Dr Russell Basser appointed as non-executive director (ASX Announcement)
The Board of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Russell Basser as an independent non-executive director, effective from 20 February 2023.
Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL.
Dr Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited / CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring / CSL Limited.
Quarterly Activities Report & Appendix 4C (ASX Announcement)
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 December 2022 (Q2 FY23).
Starpharma’s cash balance as at 31 December 2022 was $44.0 million, with a positive net operating cash flow of $2.2 million for the quarter. Total receipts of $8.1 million in the quarter include $7.1 million received from the Australian Government under its R&D tax incentive scheme and receipts from customers of $1.0 million. Customer receipts, including from sales of VIRALEZE™ and VivaGel® BV, were up 59% from the previous quarter (Q1 FY23: $0.6 million).